Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life, according to a new study. The laboratory and animal findings suggest that adding sorafenib would maintain treatment efficacy while permitting use of lower doses of chemotherapy and radiation, thereby decreasing the treatment’s harsh side effects.